drugset / Trial / NCT05271799

A Study to Evaluate Pharmacokinetic, Safety, Tolerability and Relative Bioavailability of Gepotidacin in Healthy Adult Male and Female Participants

NCT05271799

Phase 1 Completed 24 enrolled GlaxoSmithKline
RandomizedCrossoverOpen-labelTreatment

Summary

This study is a randomized, open-label, two periods, cross-over pharmacokinetic, safety, tolerability and relative bioavailability of gepotidacin in healthy adult male and female participants of aged 18 to 50 years.

Timeline

Start
2022-03-01
Primary completion
2022-04-22
Completion
2022-04-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Gepotidacin Small molecule Oral

Indications

No indication recorded.